Jagsonpal Pharmaceuticals balance sheet

As of Sep 2026

Total assets: ₹295cr−1.2% on Sep 2025
Shareholders' equity: ₹244cr−3.6% on Sep 2025
Total debt: ₹0.0crNo figure a year before
Cash and investments: ₹19.1cr+49.2% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.6	0.6	0.6	0.9	18.4
	9.7	9.7	9.7	0.0	0.0
	71.3	75.0	84.2	8.4	5.9
	20.0	0.0	0.0	0.0	0.0
	0.0	0.0	0.0	0.0	1.1
	25.2	85.1	17.4	5.2	2.6
	25.2	85.1	17.4	5.2	3.8
	0.1	0.1	0.8	1.2	0.3
	2.8	3.1	4.4	2.1	2.0
	130	174	117	17.8	30.4
	19.4	14.6	15.2	15.0	20.7
	27.0	17.2	13.2	11.0	20.9
	19.1	10.0	11.2	12.8	11.1
	94.9	96.1	118	135	104
	0.1	0.1	0.1	0.1	0.3
	141	123	142	159	136
	5.4	5.1	4.0	25.3	8.1
	166	143	161	199	165
	295	317	278	217	195
Equity
	13.2	13.4	13.3	13.2	13.1
	231	263	227	174	146
	244	276	240	187	159
	244	276	240	187	159
Liabilities
	5.9	6.6	8.7	7.6	5.2
	5.9	6.6	8.7	7.6	5.2
	1.0	1.2	0.7	0.9	1.1
	5.0	4.4	3.1	2.1	2.2
	11.8	12.2	12.4	10.5	8.5
	14.8	11.6	9.7	7.6	16.4
	16.5	12.3	12.0	8.1	8.5
	31.3	23.9	21.7	15.7	24.9
	2.0	1.3	1.0	0.8	0.4
	1.7	0.6	0.0	0.0	0.0
	4.8	2.5	3.2	2.7	2.3
	39.8	28.3	25.9	19.1	27.6
	51.6	40.5	38.3	29.7	36.1
	295	317	278	217	195
Trade payables — MSME split
	3.4	2.4	1.5	—	—
	11.4	9.2	8.3	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹230.96

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,547 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	18.4	0.9	0.6	0.6	0.6
+ Goodwill	0.0	0.0	9.7	9.7	9.7
+ Other Intangibles	5.9	8.4	84.2	75.0	71.3
+ Investments (Equity Method)	0.0	0.0	0.0	0.0	20.0
+ Non-current Investments	1.1	0.0	0.0	0.0	0.0
+ Other Non-current Financial Assets	2.6	5.2	17.4	85.1	25.2
Non-current Financial Assets	3.8	5.2	17.4	85.1	25.2
+ Deferred Tax Assets	0.3	1.2	0.8	0.1	0.1
+ Other Non-current Assets	2.0	2.1	4.4	3.1	2.8
Total Non-current Assets	30.4	17.8	117.1	173.6	129.5
Current Assets
+ Inventories	20.7	15.0	15.2	14.6	19.4
+ Trade Receivables	20.9	11.0	13.2	17.2	27.0
+ Cash & Cash Equivalents	11.1	12.8	11.2	10.0	19.1
+ Other Bank Balances	103.6	135.2	117.5	96.1	94.9
+ Other Current Financial Assets	0.3	0.1	0.1	0.1	0.1
Current Financial Assets	135.8	159.0	142.0	123.4	141.1
+ Other Current Assets	8.1	25.3	4.0	5.1	5.4
Total Current Assets	164.6	199.3	161.2	143.1	165.9
Total Assets	194.9	217.1	278.3	316.7	295.4
Equity
+ Equity Share Capital	13.1	13.2	13.3	13.4	13.2
+ Other Equity / Reserves	145.8	174.2	226.7	262.8	230.6
Equity — Owners of Parent	158.9	187.4	240.0	276.2	243.8
Total Equity	158.9	187.4	240.0	276.2	243.8
Liabilities
+ Other Non-current Financial Liab	5.2	7.6	8.7	6.6	5.9
Non-current Financial Liabilities	5.2	7.6	8.7	6.6	5.9
+ Provisions — Non-current	1.1	0.9	0.7	1.2	1.0
+ Deferred Tax Liabilities	2.2	2.1	3.1	4.4	5.0
Non-current Liabilities	8.5	10.5	12.4	12.2	11.8
+ Trade Payables	16.4	7.6	9.7	11.6	14.8
+ Other Current Financial Liab	8.5	8.1	12.0	12.3	16.5
Current Financial Liabilities	24.9	15.7	21.7	23.9	31.3
+ Provisions — Current	0.4	0.8	1.0	1.3	2.0
+ Current Tax Liabilities	0.0	0.0	0.0	0.6	1.7
+ Other Current Liabilities	2.3	2.7	3.2	2.5	4.8
Current Liabilities	27.6	19.1	25.9	28.3	39.8
Total Liabilities	36.1	29.7	38.3	40.5	51.6
Total Equity & Liabilities	194.9	217.1	278.3	316.7	295.4
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	1.5	2.4	3.4
+ Dues to Other Creditors — Current	—	—	8.3	9.2	11.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.